Celyad announced that the results of ongoing Phase I and Deplethink studies evaluating CYAD-01 for the treatment of refractory and / or recurrent acute myeloid leukemia (AMR r / r) and myelodysplastic syndrome (MDS) continue to support the clinical development of the product candidate CAR-T based NKG2D.
Preliminary data from cohort 10 of the Think trial evaluating a more dense CYAD-01 schedule without preconditioning showed better cell engraftment than bi-monthly injections of CYAD-01 without preconditioning.
The first results of the Deplethink trial evaluating a single CYAD-01 administration after preconditioning chemotherapy demonstrated that the treatment was well tolerated with better T-CSC engraftment over time compared to the segment of the Try to increase the dose with a cycle of three injections of CYAD-01.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.